Metabolic syndrome and low high-density lipoprotein cholesterol are associated with adverse pathological features in patients with prostate cancer treated by radical prostatectomy
Urologic Oncology: Seminars and Original Investigations | Nov 22, 2017
An update of research evidence on nutrition and prostate cancer
Urologic Oncology: Seminars and Original Investigations | Nov 20, 2017
Abiraterone acetate + prednisolone treatment beyond prostate specific antigen and radiographic progression in metastatic castration-resistant prostate cancer patients
Urologic Oncology: Seminars and Original Investigations | Nov 18, 2017
Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: The STAAR study
Urologic Oncology: Seminars and Original Investigations | Nov 18, 2017